Autonomix Taps Brad Hauser as President & CEO

Autonomix Medical has appointed Brad Hauser as its new president and CEO, effective immediately. Former president and CEO Lori Bisson was named executive chairman and will continue to guide the company.
 
Hauser boasts over 20 years of experience in unique, energy-based technologies. He has been a visionary for laser, radiofrequency, sound, and cold technologies to treat indications from vascular to adipose tissue to skin.
 
He most recently served as chief operating officer at skin health firm Beauty Health. There he led operations, marketing, technology, R&D, quality assurance, and regulatory affairs. He also headed product development with focus on advancing the HydraFacial delivery systems.
 
Hauser was previously part of teams that successfully took three companies through acquisition: Soliton, ZELTIQ Aesthetics, and Reliant Technologies. He was also an officer of four public companies.
 
“Several of our team members and I have had the pleasure of working with Brad at a prior company and his leadership style is a perfect fit for the next phase of Autonomix’s development,” said Bisson. “In particular, his prior extensive experience with tissue coagulation and ablation systems brings a significant value and successful track record, in addition to his history of blending clinical and regulatory development with product manufacturing and launch, which truly makes him the ideal candidate and optimal time for this next step in our company’s growth. We are all thrilled to be working with him again.”
 
“I couldn’t be more excited by this opportunity and to team up again with these proven leaders to fill an important unmet need for patients and their families with the goal of building significant value for our shareholders,” added Hauser. “I have spent the majority of my career working closely with physicians and partnering with them to advance novel technologies and I believe that Autonomix has the potential to transform patient outcomes and revolutionize how diseases involving the nervous system are diagnosed and treated. The preclinical and initial proof of concept data are highly compelling, and we will continue to expeditiously advance our clinical program in order to seek regulatory approvals globally.”

More about Autonomix Medical

The company focuses on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated.
 
The company’s first-in-class technology platform includes a catheter-based microchip sensing array that can detect and differentiate neural signals with about 3,000 times greater sensitivity than currently available technologies.